



## Bayer – Update to Recall of Kogenate<sup>®</sup> FS antihemophilic factor (recombinant)

- On July 19, 2019, [Bayer announced](#) a consumer-level recall of two lots of [Kogenate<sup>®</sup> FS antihemophilic factor \(recombinant\)](#) 2000 IU vials because some of these vials contained [Jivi<sup>®</sup> antihemophilic factor \(recombinant\) PEGylated-auct](#) 3000 IU.
  - Further information about this recall is found in a previous RxNews (from July 19).
- Although an initial claims assessment did not indicate that any members were affected, a second review of the data did identify that some members were impacted. Therefore, Clinical Services will conduct mailings to members that may be affected by the Kogenate FS recall, and to providers who prescribed for Kogenate FS recently.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.